ScoreWhy is Aarey Drugs & Pharmaceuticals Ltd ?
1
Weak Long Term Fundamental Strength with a -159.74% CAGR growth in Operating Profits over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 1.87
- The company has been able to generate a Return on Equity (avg) of 4.20% signifying low profitability per unit of shareholders funds
2
The company has declared Negative results for the last 3 consecutive quarters
- PAT(9M) At Rs 2.86 cr has Grown at -42.69%
- PBT LESS OI(Q) At Rs 0.69 cr has Fallen at -60.12%
- NET SALES(Q) At Rs 84.16 cr has Fallen at -19.95%
3
Risky - Negative Operating Profits
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 19.96%, its profits have fallen by -40.4%
4
Falling Participation by Institutional Investors
- Institutional investors have decreased their stake by -0.84% over the previous quarter and collectively hold 1.13% of the company
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Aarey Drugs for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Aarey Drugs
31.31%
0.44
44.97%
Sensex
-4.3%
0.43
11.83%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
8.05%
EBIT Growth (5y)
-230.47%
EBIT to Interest (avg)
1.90
Debt to EBITDA (avg)
7.02
Net Debt to Equity (avg)
0.30
Sales to Capital Employed (avg)
2.85
Tax Ratio
40.28%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
3.86%
ROCE (avg)
2.55%
ROE (avg)
4.20%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
44
Industry P/E
21
Price to Book Value
1.05
EV to EBIT
-51.70
EV to EBITDA
-143.70
EV to Capital Employed
1.04
EV to Sales
0.50
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-0.07%
ROE (Latest)
2.36%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend1What is working for the Company
CASH AND CASH EQUIVALENTS(HY)
Highest at Rs 7.19 cr
-11What is not working for the Company
NET SALES(Q)
At Rs 96.43 cr has Fallen at -27.92%
PBT LESS OI(Q)
At Rs -3.26 cr has Fallen at -552.78%
NON-OPERATING INCOME(Q)
is 454.35 % of Profit Before Tax (PBT
Loading Valuation Snapshot...
Here's what is working for Aarey Drugs
Cash and Cash Equivalents - Half Yearly
Highest at Rs 7.19 cr
in the last six half yearly periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Here's what is not working for Aarey Drugs
Net Sales - Quarterly
At Rs 96.43 cr has Fallen at -27.92%
Year on Year (YoY)MOJO Watch
Near term sales trend is very negative
Net Sales (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs -3.26 cr has Fallen at -552.78%
Year on Year (YoY)MOJO Watch
Near term PBT trend is very negative
PBT less Other Income (Rs Cr)
Non Operating Income - Quarterly
is 454.35 % of Profit Before Tax (PBT)
MOJO Watch
The company's income from non business activities is high; which is not a sustainable business model
Non Operating Income to PBT
